A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2017
At a glance
- Drugs Ad-GMCAIX transduced dendritic cells (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 11 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 07 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016, according to ClinicalTrials.gov record.
- 17 Apr 2013 New trial record